Abstract
The Nipah virus (NiV) outbreak was declared in Kozhikode district, Kerala state, India on September 12, 2023. The local, state, and national authorities worked in an integrated way to tackle and control the outbreak. Indian Council of Medical Research (ICMR) deployed a team from ICMR-National Institute of Virology (NIV), Pune, India along with an indigenously developed and validated Mobile BSL-3 (MBSL-3) laboratory for providing onsite NiV diagnosis. The Kozhikode district of Kerala state has been an epicenter of three NiV outbreaks in May 2018, August 2021, and recently in September 2023. The Ernakulam district, Kerala also reported NiV outbreak in June 2019. In the 2023 outbreak, six confirmed NiV cases were detected with two deaths. During previous outbreaks in 2019 and 2021, the team from ICMR-NIV, Pune had successfully established the field laboratory utilizing the BSL-2 facility for NiV onsite diagnosis. The BSL-3 personnel protective equipment and standard operative procedures were used to handle the clinical specimens. Post COVID-19 pandemic, under the pioneering initiative of the Government of India, ICMR and Klenzaids Contamination Control Pvt Ltd, Mumbai developed a rapidly deployable, pragmatic, access control and containment laboratory on bus chassis. This MBSL-3 laboratory was utilized for the NiV onsite diagnosis for early containment of outbreak reducing the turnaround time to diagnosis to just 4 hours. MBSL-3 laboratory played a significant role in NiV outbreak response and could be utilized in the future also reaching the remotest areas of the country.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The grant was provided from the Indian Council of Medical Research New Delhi India under the extramural project Sustainable laboratory network for monitoring of Viral Haemorrhagic Fever viruses in India and enhancing bio-risk mitigation for High risk group pathogen with the grant number: VIR/28/2020/ECD-1 dated 10.05.2023. The funders had no role in study design data collection and analysis decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Human Ethics Committee of ICMR-National Institute of Virology Pune India under the project Sustainable laboratory network for monitoring of Viral Haemorrhagic Fever viruses in India and enhancing bio-risk mitigation for High risk group pathogens [NIV/IEC/March/2021/D-9 dated 9 April 2021]. No patient related data has been included in this manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data related to this study has been included in the manuscript
